[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chang Gung Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":670},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,153,0,25,[9,50,81,109,135,157,190,208,233,262,288,317,342,367,391,423,450,473,501,532,555,580,604,625,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100652907","personalized-sensory-stimulation-urban-and-rural-dementia-care-100652907",false,"NCT07778277","Personalized Sensory Stimulation: Urban and Rural Dementia Care","Smart Brain Health Promotion Service Integrating Personalized Sensory Stimulation: Practical Validation and Application in Urban and Rural Dementia Care Centers","Inclusion Criteria:\n\n* Aged ≥ 60 years\n* The score of MoCA between 10 to 25\n\nExclusion Criteria:\n\n* Diagnosis of other psychiatric or neurological disorders, and those with a history of neurological or psychiatric disorders that may affect cognitive assessment or performance. For example (but not limited to): Parkinson's disease, schizophrenia, major depressive disorder, epilepsy, severe traumatic brain injury with loss of consciousness, and stroke.\n* Drug, Nicotine or alcohol addictions\n* Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.","ALL","60 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","As Taiwan transitions into a super-aged society, rising dementia rates have severely strained long-term care systems. Although current daycare centers provide multi-modal programs, they remain limited to behavioral training, lacking precise interventions targeting brain function and neuroplasticity or integrated non-invasive neuromodulation technologies. Furthermore, urban-rural disparities in resources, staffing allocation, and tech experience hinder practical deployment, with empirical research remaining scarce. Addressing this gap, this study investigates a smart brain health promotion model combining personalized gamma music stimulation and cognitive training for mild cognitive impairment and dementia, while evaluating its feasibility across diverse care settings.",[27,28,29,30,31],"Dementia","Acoustic Stimulation","Healthcare Disparities","Precision Medicine","Cognitive Training",[27,33,34,35,36],"Gamma frequency auditory tone","Personalize intervention","Urban-rural disparities","Cognitive training","NOT_YET_RECRUITING","2026-08-18",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":21},"2026-09-20",{"date":45,"type":21},"2028-09-20",{"name":47,"class":48},"Chang Gung Memorial Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100618786","phase-2-dostarlimab-cisplatin-and-etoposide-in-combination-with-radiotherapy-in-sandwich-sequence-for-small-cell-neuroendocrine-cervical-carcinoma-100618786","NCT07336147","Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma","Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma (DICER Trial): Taiwanese Gynecologic Oncology Group (TGOG) 1012","Inclusion Criteria:\n\n1. Female participants who are 20-70 years of age on the day of signing informed consent with histologically confirmed diagnosis of Previously untreated SCNECC IB2-IV or IB1 with LVSI or IVB with oligometastasis (only in one distant organ not more than 2 nodules which can be encompassed by RT) will be enrolled in this study.\n\n   \\*A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to participate this trial should be informed that after the protocol treatment the ovarian function and child-bearing potential will be permanently lost and she has to follow the contraceptive guidance in Appendix 3 after enrollment through neoadjuvant chemoimmuntherapy period till external beam radiotherapy (EBRT) commences.\n2. Have provided archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archival tissue. At least 5 punch biopsiesdof 3mm in diameter.\n3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n   Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n3. Has received prior systemic anti-cancer therapy for SCNECC including investigational agents prior to enrollment.\n4. Has received prior pelvic radiotherapy.\n5. Has received radical surgery for cervical cancer.\n6. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.\n7. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n8. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n9. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n10. Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention.\n11. Has severe hypersensitivity (≥Grade 3) to dostarlimab and\u002For any of its excipients.\n12. Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n13. Has a history of (non-infectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease.\n14. Has an active infection requiring systemic therapy.\n15. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.\n16. Has a known history of untreated Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus infection (for those with anti-HCV+, patients who ever HCV RNA positive should undergo 8-12 weeks direct acting agents (DAA) treatment and confirmed with HCV cure, defined as HCV RNA negative at week 12 post end-of-treatment). Note: Testing for Hepatitis B and Hepatitis C is required but the patient is eligible if well controlled.\n17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n18. Allergy: Participant cannot have history of severe allergic and\u002For anaphylactic reactions to chimeric, human or humanized antibodies or fusion proteins, sensitivity to any of the study treatments or components thereof, or a history of drug or other allergy that contraindicates their participation.\n19. Has had an allogenic tissue\u002Fsolid organ transplant.\n20. Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.\n21. Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal\u002Fgastric varices, or persistent jaundice.\n\nNote: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.\n\n\\-","FEMALE","20 Years","70 Years",{"count":61,"type":21},45,[63],"PHASE2","Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC",[66],"Female",[68,69,70,71],"dostarlimab","cisplatin","etoposide","cervical carcinoma","RECRUITING","2026-08-14",{"date":75,"type":41},"2026-08-17",{"date":77,"type":41},"2025-12-22",{"date":79,"type":21},"2030-12-22",{"name":47,"class":48},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100599704","efficacy-of-gamma-auditory-stimulation-for-cognitive-decline-in-older-adults-study-1-100599704","NCT07087951","Efficacy of Gamma Auditory Stimulation for Cognitive Decline in Older Adults (Study 1)","Development and Validation of an Innovative Gamma Auditory Stimulation System for Older Adults With Cognitive Decline: A Randomized, Double-blind, Placebo-controlled Study (Study 1)","Inclusion Criteria:\n\n1. Age over 60 years old.\n2. MMSE≤ 24\n3. CDR scores of 0.5 and 1\n4. Voluntary to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Diagnosis of other psychiatric or neurological disorders\n2. Drug or alcohol addictions.\n3. Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.\n4. History of clinical stroke, major depressive disorder or dysthymic disorder according to the DSM-5.",{"count":89,"type":21},70,[24],"Animal studies have shown that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, human studies using 40 Hz auditory stimulation alone remain limited. Therefore, this study will use a randomized, double-blind, placebo-controlled design to investigate the effects of 40 Hz auditory stimulation on cognitive function, EEG activity, sleep quality, and quality of life in older adults with mild cognitive impairment (MCI) or mild dementia.",[93,94,95],"EEG Brain Oscillations","Alzheimer's Disease (AD) and Related Disorders","Cognitive Dysfunction",[97,98,99,100,101,102],"endogenous gamma","EEG rhythms","resting-state EEG (rs-EEG)","Alzheimer's disease (AD)","Cognitive function","auditory stimulation",{"date":75,"type":41},{"date":105,"type":41},"2025-11-14",{"date":107,"type":21},"2028-11-01",{"name":47,"class":48},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":116,"enrollmentInfo":117,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":49},"100533069","to-assess-the-impact-of-theeras-consensus-on-patients-with-endoscopic-pituitary-tumor-surgery-100533069","NCT06221020","To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery","To Assess the Impact of the Enhanced Recovery After Surgery (ERAS) Consensus on the Effectiveness and Prognosis of Patients With Endoscopic Pituitary Tumor Surgery","Inclusion Criteria:\n\n* Clinical diagnosis of pituitary tumors\n* To sign a written informed consent form\n\nExclusion Criteria:\n\n* Diagnosed with other malignant tumors\n* Severe infections, such as osteomyelitis, acute inflammation at the affected site, or open wounds at the treatment area\n* Pregnant women\n* Coagulation disorders or those taking anticoagulant medication\n* Other central nervous system disorders, alcohol addiction, other addictive drugs, or mental illness that may affect clinical assessment\n* Deemed unsuitable for surgical treatment or unable to comply with clinical evaluation upon assessment","75 Years",{"count":89,"type":21},"3 Months","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness and impact of Enhanced Recovery After Surgery (ERAS) on patients with pituitary gland tumors.",[122,123,124],"Enhanced Recovery After Surgery","Pituitary Tumor","Postoperative Complications",[122,126,127,124],"Pituitary tumor","Anesthesia Safety","2026-08-13",{"date":75,"type":41},{"date":131,"type":41},"2023-12-12",{"date":133,"type":21},"2026-11-30",{"name":47,"class":48},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100581524","ovarian-cancer-identification-on-ct-using-deep-learning-100581524","NCT06851429","Ovarian Cancer Identification on CT Using Deep Learning","Development and Validation of a Deep Learning Model for Ovarian Cancer Identification on CT: A Nationwide Population-Based and International Study","Inclusion Criteria:\n\n1. Age ≥ 20 years old.\n2. Female\n3. undergone a CT scan\n4. undergone a CT scan within 180 days prior to ovarian surgery for histopathological evaluation.\n\nExclusion Criteria:\n\n1. Age \\\u003C 20 years old.\n2. Non-female\n3. Non-CT imaging\n4. Incorrect image orientation\n5. Number of slices \\\u003C 10\n6. Slice thickness \\>10 mm or \\\u003C 1 mm\n7. Unsuccessful DICM-to-NIfTI\n8. Pelvic subvolume extraction failed\n9. Non-contrast CT scans\n10. Metallic artifacts\n11. Inconclusive cases",true,{"count":144,"type":21},12578,"Ovarian cancer remains the deadliest gynecologic malignancy, with poor survival rates largely due to late-stage diagnosis. Early detection is crucial, yet no universally accepted screening method exists. Current imaging techniques and biomarkers, such as CA-125, have limitations in specificity and sensitivity. This study aims to develop and evaluate a deep learning-based computer-aided diagnosis tool (CAT-OV), for ovarian cancer detection using CT imaging. The system integrates a Body Part Regression (BPR) model for pelvic localization and a Multiple Instance Learning (MIL) ensemble classifier for cancer prediction. The model was trained and validated using retrospective datasets from Taiwan, the United States, and a nationwide real-world cohort. Stringent preprocessing and quality control measures were implemented to enhance model accuracy. Results highlight the potential of AI-driven CT screening in improving early detection, though further validation is needed for clinical adoption.",[147],"Ovarian Cancer","2026-08-10",{"date":150,"type":41},"2026-08-12",{"date":152,"type":41},"2022-09-01",{"date":154,"type":21},"2028-08-31",{"name":47,"class":48},2,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100542172","cerebrolysin-after-extended-window-endovascular-thrombectomy-100542172","NCT06339411","Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy","Cerebrolysin After Reperfusion in Extended-Window Endovascular Thrombectomy: A Multicenter Randomized Controlled Trial","CARE-EVT","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Acute anterior-circulation ischemic stroke caused by internal carotid artery or M1 or M2 middle cerebral artery occlusion confirmed by computed tomography angiography.\n* Stroke onset-to-groin-puncture interval greater than 6 hours and no more than 24 hours.\n* Prestroke modified Rankin Scale score of 0 to 2.\n* Baseline National Institutes of Health Stroke Scale score of at least 6 with cortical signs.\n* Alberta Stroke Program Early Computed Tomography Score greater than 3.\n* Computed tomography perfusion target mismatch defined as ischemic core volume less than 70 mL, mismatch ratio at least 1.8, and mismatch volume at least 15 mL.\n* Moderate-to-good collateral circulation, defined as filling of more than 50% of the middle cerebral artery territory on computed tomography angiography.\n* Successful endovascular reperfusion, defined as modified Thrombolysis in Cerebral Infarction grade 2b or 3, confirmed before randomization.\n* Study treatment can be initiated within 36 hours of stroke onset.\n* Written informed consent obtained before randomization from the participant or a legally authorized representative.\n\nExclusion Criteria:\n\n* Life expectancy less than 6 months or a serious medical, neurological, or psychiatric condition likely to interfere with study treatment, follow-up, or outcome assessment.\n* Current pregnancy or breastfeeding.\n* Known iodinated contrast allergy that precludes required endovascular or imaging procedures.\n* Acute or chronic renal failure with creatinine clearance less than 30 mL\u002Fmin.\n* Known hypersensitivity or contraindication to Cerebrolysin.\n* Aspartate aminotransferase or alanine aminotransferase greater than 2 times the upper limit of normal, or total bilirubin greater than 2 mg\u002FdL.\n* Blood glucose less than 50 mg\u002FdL or greater than 400 mg\u002FdL.\n* Platelet count less than 50,000\u002Fmm3 or international normalized ratio greater than 3.\n* Seizure at stroke onset that prevents reliable neurological assessment.\n* Pre-existing intracranial hemorrhage or multiple vascular occlusions on baseline neuroimaging.","18 Years","80 Years",{"count":168,"type":21},100,[63],"Acute ischemic stroke caused by blockage of a large brain artery can lead to severe disability. Endovascular thrombectomy is a catheter-based procedure used to remove the blood clot and restore blood flow. It can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery.\n\nThis multicenter randomized clinical trial will evaluate whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery. The study will enroll 100 adults aged 18 to 80 years at three stroke centers in Taiwan. Participants will be randomly assigned, after successful reperfusion has been confirmed, to receive either Cerebrolysin 30 mL or a matched normal saline placebo by intravenous infusion once daily for 10 consecutive days. The first infusion will begin within 36 hours of stroke onset. All participants will also receive standard stroke care and rehabilitation.\n\nThe primary outcome is final infarct volume measured by diffusion-weighted magnetic resonance imaging on Day 7 to Day 10. Other outcomes include functional recovery at 3 and 12 months, neurological improvement, symptomatic intracranial hemorrhage, cerebral edema, recurrent stroke, mortality, cognition, language, and mood. The study will also examine blood-brain barrier injury using computed tomography perfusion, dynamic contrast-enhanced magnetic resonance imaging, and serial plasma Claudin-5 measurements.\n\nThis study will determine whether Cerebrolysin shows evidence of reducing postreperfusion brain injury after successful thrombectomy and will help guide the design of a larger trial focused on clinical outcomes.",[172],"Acute Ischemic Stroke",[174,175,176,177,178,179,180,181],"Endovascular Thrombectomy","Large Vessel Occlusion","Extended Time Window","Cerebrolysin","Blood-Brain Barrier","Claudin-5","Neuroprotection","Computed Tomography Perfusion","2026-08-09",{"date":184,"type":41},"2026-08-11",{"date":186,"type":21},"2026-09-01",{"date":188,"type":21},"2030-12-31",{"name":47,"class":48},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":207,"locationsCount":49},"100651194","regional-nerve-block-for-upper-extremity-surgery-in-patients-with-sarcopenia-100651194","NCT07757984","Regional Nerve Block for Upper Extremity Surgery in Patients With Sarcopenia","Inclusion Criteria:\n\n* Age\\>=50 years old\n* ASA I-III\n* Receiving upper limb surgery under general anesthesia\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to cooperate with pain and motor assessment\n* Pre-existing neuropathy of the musculocutaneous, median, radial or ulnar nerve\n* (for nerve block group) Contraindications to regional nerve blockade","50 Years",{"count":198,"type":21},150,"The goal of this observational study is to learn about the impact of sarcopenia (muscle loss) on the efficacy of regional nerve blocks and postoperative recovery in patients undergoing upper extremity surgery. The main questions it aims to answer are:\n\n1. Does sarcopenia affect the onset time and success rate of peripheral nerve blocks?\n2. How does sarcopenia influence postoperative pain control and opioid consumption compared to patients receiving pure general anesthesia?\n\nParticipants will undergo a preoperative muscle assessment, which includes a chair stand test and a brief ultrasound of the thigh muscle. Researchers will then observe and record their nerve block onset time (if applicable), postoperative pain scores, and recovery metrics during their hospital stay up to postoperative day 2.",[201,202],"Sarcopenia","Nerve Block","2026-08-06",{"date":184,"type":41},{"date":186,"type":21},{"date":154,"type":21},{"name":47,"class":48},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":166,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":49},"100567337","skeletal-muscle-mass-changes-on-images-for-prediction-of-prognosis-after-exercise-training-in-hnscc-patients-100567337","NCT06666881","Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients","(Health Promotion) Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in Head and Neck Cancer Patients","Inclusion Criteria:\n\n1. Age ≥20\n2. Pathology:Squamous cell carcinoma\n3. Need CCRT treatment\n4. ECOG PS\\\u003C2\n5. Agree with blood drawing, exercise training, and all the procedures in the trial.\n\nExclusion Criteria:\n\n1. ECOG PS≥2\n2. Participants with intolerance basic exercise training, or without CCRT treatment\n3. Mental illness or any medical illness or concurrent illness that may be aggravated by exercise training or unmanageable\n4. Any medical condition that unsuitable for exercise training\n5. refure to do the trial procedures: exercise training, blood drawing and all the procedures in the trial.\n6. can't get the data for the whole-body computed tomography",{"count":216,"type":21},60,[24],"This project adopts a prospective study design. It is scheduled to enroll 60 participants diagnosed with Head and Neck cancer in this hospital, of which 30 are in the experimental group and 30 are in the control group. The purpose of this research is to analyze the skeletal muscle mass changes on images in Head and Neck cancer patients after exercise training and the association with systemic inflammatory markers. Investigators would like to know whether these images and biomarkers predict the prognosis of Head and Neck cancer. Subjects enrolled in the trial will receive 36 times of exercise training after concurrent chemoradiotherapy. Before and after the completion of exercise training, investigators will arrange (1) dual energy X-ray absorptiometry (DXA) to measure the whole-body skeletal muscle mass and appendicular skeletal muscle mass and (2) blood tests for markers of systemic inflammation. In addition to DXA, computed tomography (CT) is another image modality for skeletal muscle mass evaluation. Positron emission tomography - CT or whole-body CT for cancer staging are considered as baseline studies. The routine follow-up CT images are used to analyze the changes after exercise training. If magnetic resonance imaging is also performed during the follow-up period, images will also be collected and assessed as an alternative.If the experimental group can maintain or even improve skeletal muscle mass and can be reflected in blood tests and prognosis, the result may be able to apply on cancer treatment and disease followup.",[220,221],"Head and Neck Cancer","Skeletal Muscle",[223,224,225,226],"exercise training","dual energy X-ray absorptiometry","sarcopenia","head and neck cancer",{"date":148,"type":41},{"date":229,"type":41},"2023-06-06",{"date":231,"type":21},"2027-09-30",{"name":47,"class":48},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":116,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":49},"100618547","helo-trial-energy-based-therapies-vs-conventional-hemorrhoidectomy-for-grade-iii-hemorrhoids-100618547","NCT07333040","HELO Trial: Energy-Based Therapies vs. Conventional Hemorrhoidectomy for Grade III Hemorrhoids","Hemorrhoidectomy, Energy-Based, and Laser Outcomes in Grade III Hemorrhoids: A Prospective, Multicenter, Preference-Based Comparative Study","HELO","Inclusion Criteria:\n\n* Diagnosed with Goligher Grade III internal hemorrhoids.\n* Symptomatic with HDSS score \\>= 5.\n* Age 18-75 years.\n* Fit for general anesthesia or sedation.\n* Able to provide informed consent.\n* Agree to pre-operative photo documentation.\n\nExclusion Criteria:\n\n* Other anorectal diseases (fistula, abscess, IBD, malignancy).\n* Prior anorectal surgery within 6 months.\n* Pregnancy or lactation.\n* Contraindications to anesthesia.",{"count":216,"type":21},[24],"This prospective, multicenter study compares the efficacy and functional outcomes of three surgical treatments for symptomatic Goligher Grade III internal hemorrhoids: Laser Hemorrhoidoplasty (LHP), Hemorrhoid Energy Therapy (HET), and conventional closed hemorrhoidectomy (Ferguson technique). Due to strong patient preferences in hemorrhoidal surgery, this study utilizes a pragmatic, preference-tolerant design. Eligible patients will undergo standardized counseling and select their preferred treatment arm. The study aims to evaluate whether minimally invasive energy-based therapies offer superior postoperative pain relief and faster functional recovery compared to conventional hemorrhoidectomy",[245,246,247],"Hemorrhoids Third Degree","Internal Hemorrhoids","Mixed Hemorrhoids",[249,250,251,252,253],"Laser Hemorrhoidoplasty","Hemorrhoid Energy Therapy","Postoperative Pain","Minimally Invasive Surgery","Hemorrhoidectomy","2026-08-05",{"date":256,"type":41},"2026-08-07",{"date":258,"type":41},"2026-07-01",{"date":260,"type":21},"2028-03-01",{"name":47,"class":48},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":142,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100605910","phase-2-partial-immune-boost-tace-in-unresectable-hcc-patients-under-systemic-treatment-100605910","NCT07168668","Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","EXploring Clinical Efficacy of Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment (EXPECT Trial)","EXPECT","inclusion criteria:\n\n1. Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \\\u003C 20 cm, and no one lesion \\> 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:\n\n   Histologically or cytologically proven diagnosis of HCC. Typical arterial enhancement and delayed washout on multiphasic CT or MRI.\n2. Age ≥18 years at the time of signing informed consent document.\n3. ECOG performance status 0-1.\n4. Barcelona Clinic Liver Cancer (BCLC) stages B or C.\n5. Child-Pugh score 5-6 liver function within 28 days of study registration.\n6. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.\n7. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.\n8. Ability to understand and the willingness to sign a written informed consent document\n9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration\n\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm3\n   * Platelet count ≥ 50,000\u002FμL\n   * Total bilirubin \\\u003C 2.5 mg\u002FdL\n   * Serum albumin \\>2.8 g\u002FdL\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)\n   * Prothrombin time ≤ 6 seconds prolonged\n   * Serum creatinine ≤ 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n1. Prior invasive malignancy unless disease free for a minimum of 2 years\n2. Prior radiotherapy to the region of the liver that would result in overlap of embolization fields\n3. Prior selective internal radiotherapy\u002Fhepatic arterial yttrium therapy, at any time\n4. Untreated active hepatitis B or hepatitis C\n5. Moderate to severe or intractable ascites\n6. Untreated or incomplete treated esophageal or gastric varices\n7. Severe, active co-morbidity, defined as follows:\n\n   * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months prior to registration\n   * Myocardial infarction within the last 6 months prior to study entry\n   * Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry\n   * A bleeding episode within 6 months prior to study entry due to any cause. o Thrombolytic therapy within 28 days prior to study entry.\n   * Known bleeding or clotting disorder.\n   * Uncontrolled psychotic disorder\n8. Pregnancy or women of childbearing potential and men who are sexually active and not willing\u002Fable to use medically acceptable forms of contraception\n9. Prior solid organ transplantation.\n10. Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.\n11. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.\n12. Known HIV infection.",{"count":20,"type":21},[63],"Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4; anti-CTLA4) have recently been established as a standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). However, its objective response rate (ORR) is only less than 27% (1, 2), and the majority of patients died of HCC progression and liver failure. Therefore, there is an urgent need to develop a novel combination treatment strategy to overcome resistance to immunotherapy and improve patient outcomes.\n\nTransarterial chemoembolization (TACE) remains the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) (3, 4). However, in our previous retrospective study (5-7), the investigators consistently observed that this combination not only improves therapeutic responses but also significantly prolongs patient survival. The tumor necrosis caused by TACE may enhance the efficacy of systemic therapies by promoting the release of neoantigens, thereby stimulating immune responses (8-14). This concept has been substantiated in two recent trials involving intermediate-stage HCC (15, 16), where the addition of immune checkpoint inhibitors to TACE resulted in improved clinical outcomes. Nevertheless, this promising approach has yet to replace the decades-old standard treatment protocols, underscoring the need for further proof-of-concept studies.\n\nBoth immunotherapy (atezolizumab\u002Fbevacizumab or durvalumab\u002Ftremelimumab) and transarterial chemoembolization (TACE) are approved treatment modalities for unresectable hepatocellular carcinoma (HCC) by the U.S. and Taiwan Food and Drug Administration (FDA). This phase II non-randomized trial is designed to prospectively evaluate the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with a combination of immunotherapy and TACE. A particular focus of this study is to explore the potential immune-boosting effects of TACE, including its ability to enhance antigen presentation and stimulate anti-tumor immune responses.",[274,275,276],"HCC","Tace","Immunotherapy",[278,279,280],"hepatocelluar carcinoma","transarterial chemoembolization","immunotherapy","2026-08-04",{"date":203,"type":41},{"date":284,"type":21},"2026-09-15",{"date":286,"type":21},"2029-08-14",{"name":47,"class":48},{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":49},"100643204","ctdna-monitoring-after-pancreatic-cancer-surgery-k-4care-lite-study-100643204","NCT07597252","ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)","A Prospective Observational Study of Circulating Tumor DNA Dynamic Monitoring Using K-4CARE Lite Platform After Curative Resection of Pancreatic Cancer","K4CARE-PDAC","Inclusion Criteria:\n\n* Age 20 years or older\n* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), including its histological subtypes\n* Has undergone curative-intent resection (R0 or R1, defined as margin \\\u003C1 mm), via pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy\n* Post-operative pathologic stage at least pT1, with N0 or N1 or higher\n* Computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks before enrollment confirming no evidence of residual tumor and no distant metastasis\n* Intent to receive adjuvant chemotherapy\n* Sufficient surgical FFPE tumor tissue available for genomic sequencing\n* Able to understand and provide signed informed consent\n* Patients with or without prior neoadjuvant chemotherapy are both eligible\n\nExclusion Criteria:\n\n* Post-operative pathologic stage IV (distant metastasis), or R2 resection\n* Concurrent active primary malignancy (except cured non-melanoma skin cancer or carcinoma in situ within the past 5 years)\n* Severe post-operative complications precluding initiation of adjuvant chemotherapy within 12 weeks\n* Receipt of post-operative radiation therapy\n* Known hematologic disease or myeloproliferative disorder that may significantly affect ctDNA assay accuracy\n* Pregnant or breastfeeding women\n* Unable to comply with the protocol-specified blood draw schedule",{"count":297,"type":21},30,"Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years. Current post-operative surveillance relies on computed tomography (CT) imaging and the serum tumor marker CA 19-9, but both have limited sensitivity for detecting microscopic residual disease.\n\nThis single-center, prospective observational study evaluates the use of the K-4CARE Lite platform-a tumor-informed plus tumor-agnostic circulating tumor DNA (ctDNA) assay with a limit of detection of 0.005%-for dynamic monitoring of minimal residual disease (MRD) in patients with resected PDAC.\n\nThirty adult patients who have undergone R0 or R1 (margin \\\u003C1 mm) resection at Linkou Chang Gung Memorial Hospital will be enrolled over 24 months. Each participant will provide one baseline tumor tissue sample (formalin-fixed paraffin-embedded) and three serial blood samples at three pre-specified study timepoints: Timepoint 1 (Week 4 to Week 10 after surgery, before adjuvant chemotherapy); Timepoint 2 (12 weeks after Timepoint 1, approximately 3 months into adjuvant chemotherapy); and Timepoint 3 (at completion of adjuvant chemotherapy, approximately Month 6 after surgery). A fourth long-term follow-up phase (Timepoint 4) collects results from patient-funded ctDNA testing performed as part of routine care.\n\nThe primary outcome is the cumulative MRD detection rate across the three pre-specified post-surgical timepoints (Timepoint 1, Timepoint 2, and Timepoint 3). Secondary outcomes include the association between ctDNA status and disease-free survival (DFS) and overall survival (OS), molecular clearance rate at Timepoint 3, lead time of molecular relapse over imaging, and platform performance. ctDNA results are reported back to the treating physician for reference but do not mandate treatment changes-all clinical decisions remain at the physician's discretion per standard guidelines.\n\nThis study aims to generate the prospective evidence base needed to design future ctDNA-guided interventional trials in pancreatic cancer.",[300,301],"Pancreatic Ductal Adenocarcinoma (PDAC)","NGS Monitor MRD",[303,304,305,306,307,308,309],"pancreatic cancer","circulating tumor DNA","minimal residual disease","tumor-informed sequencing","adjuvant chemotherapy","liquid biopsy","K-4CARE Lite","2026-07-31",{"date":312,"type":41},"2026-08-03",{"date":186,"type":21},{"date":315,"type":21},"2029-04-30",{"name":47,"class":48},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":49},"100545470","the-psychological-impact-of-mindfulness-intervention-to-anterior-cruciate-ligament-reconstruction-100545470","NCT06382324","The Psychological Impact of Mindfulness Intervention to Anterior Cruciate Ligament Reconstruction","Inclusion Criteria:\n\n* Within the first month after ACL reconstruction without mindfulness practice experience\n\nExclusion Criteria:\n\n* below 18 years old, previous exposure to mindfulness intervention",{"count":324,"type":21},80,[24],"Anterior cruciate ligament (ACL) reconstruction surgery is a common procedure performed by orthopedic surgeons. Postoperatively, patients often experience pain, muscle tension, and concerns about their ability to return to sports. These factors influence the recovery and return to sports capabilities of ACL patients. According to research, only 64% of patients are able to recover to their pre-injury level after surgery, and the success rate for returning to competitive sports is only 56%. Psychological factors during the recovery process may explain this disparity. ACL injury is associated with anxiety, pain reaction, and emotional disorders, with fear of re-injury being the most common obstacle to returning to sports, accounting for 19%. A study by Lentz et al. (2015) also found no significant differences in pain assessments between individuals who were afraid of re-injury and those who were able to return to sports at six months and one year after surgery. This suggests that fear of pain may limit activity and increase the risk of unsuccessful return to sports.\n\nMindfulness intervention is a psychological approach that involves non-judgmental awareness and focus on moment to moment. Mindfulness practice is known to reduce stress in athletes, promote recovery, enhance athletic performance, and improve sleep quality. Good sleep quality contributes to emotional stability and physical recovery. Even short daytime naps can be beneficial for athletes. A review of 37 studies of moderate quality found that daytime napping can improve physical and cognitive performance, psychological state, and nighttime sleep.\n\nTherefore, investigators hypothesize that integrating mindfulness practice into daytime napping may lead to improved spirit upon waking, reduce sleep inertia, and over time, potentially increase the rate of return to sports after ACL reconstruction.",[328],"Anterior Cruciate Ligament (Acl) Reconstruction",[330,331,332,333,334],"Mindfulness","Napping","ACL injury","Return-to-sport","Polysomnography","2026-07-30",{"date":310,"type":41},{"date":338,"type":41},"2024-04-23",{"date":340,"type":21},"2027-12",{"name":47,"class":48},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":142,"sex":17,"minAge":348,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":364,"leadSponsor":366,"locationsCount":156},"100624826","integrating-systematic-data-of-medicine-to-explore-the-solution-for-healthy-aging-isdha-phase-4-100624826","NCT07414680","Integrating Systematic Data of Medicine to Explore the Solution for Healthy Aging (ISDHA) Phase 4","Inclusion Criteria:\n\n* Willing to sign a written participant consent form.\n* Males or females aged 40 or above who have participated in the \"Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging (Pilot Project),\" the \"Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging\" master planner, or the \"Integrated Systematic Medical Information to Explore Solutions for Healthy Aging\" project (not subject to exclusion criteria).\n* Males or females aged 40-59 who have participated in health checkups for employees of Chang Gung Memorial Hospital, Formosa Plastics Group, or Chang Gung University.\n* Those with a medical record of more than one year at Chang Gung Memorial Hospital.\n* Those who have resided in Taiwan for more than 180 days in the past year.\n\nExclusion Criteria:\n\n* Individuals with severe organ abnormalities, such as: heart failure (NYHA Fc ≥ III), chronic obstructive pulmonary disease (hospitalization\u002Femergency room visit or medication adjustment within the past month due to disease worsening), decompensated cirrhosis, hemodialysis, or currently undergoing cancer treatment.\n* Individuals with a history of severe autoimmune diseases.\n* Individuals with a preliminary cognitive and mental assessment score of \\\u003C26 on the Mini-Mental State Examination (MMSE) or ≥5 on the Generalized Depression Scale (GDS).\n* Individuals (who agree to undergo brain MRI) who are deemed unsuitable for MRI after evaluation (e.g., those with pacemakers, cochlear implants, or spatial phobia).\n* Individuals who have taken antibiotics within the past month.\n* Individuals whose hearing, vision, or cognitive impairments affect communication.\n* Individuals unable to stand or walk (with a walking aid) or with unsteady gait when walking.\n* Those who have undergone follow-up outpatient assessments that may affect cognitive function, including but not limited to stroke, Parkinson's syndrome, Parkinson's dementia, epilepsy, brain tumor, or a history of mental illness such as schizophrenia, severe depression, bipolar disorder, alcohol or drug abuse, or a history of loss of consciousness due to severe head trauma.\n* Those currently diagnosed with depression and undergoing treatment.\n* Those with a past medical history confirming dementia, depression, etc..\n* Those deemed unsuitable by a physician.","40 Years",{"count":350,"type":21},250,"This project aims to build up the comprehensive health database of geriatric medicine for middle-aged and elderly people in Taiwan.",[353,354,355],"Sleep Disturbance","Cognitive Change","Aging",[357,358,359,360],"dementia","depression","brain structure","system biology","2026-07-29",{"date":335,"type":41},{"date":284,"type":21},{"date":365,"type":21},"2028-12-31",{"name":47,"class":48},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":142,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":49},"100649158","hyperpolarized-13c-mri-and-radiomics-in-rectal-cancer-100649158","NCT07730541","Hyperpolarized 13C-MRI and Radiomics in Rectal Cancer","Integrated Precision Imaging for Rectal Cancer Patients Undergoing Total Neoadjuvant Therapy: Hyperpolarized 13C-MRI, Metabolomics, and Radiomics","DNP_RECA","Inclusion Criteria:\n\n1. Patients with biopsy proved rectal adenocarcinoma.\n2. Patents will undergo neoadjuvant chemoradiation therapy (nCRT).\n3. Patients more than 20-year-old.\n\nExclusion Criteria:\n\n2\\. Contraindication to MRI study (e.g., claustrophobia or non-removable devices or implants that are incompatible with MRI). 3. Intercurrent illness that will affect the compliance of the patient during the MRI study (e.g., active infection, symptomatic congestive heart failure, uncontrollable angina, arrhythmia, psychiatric disorders, dyspnea, or diarrhea). 4. Severe hepatic dysfunction (alkaline phosphatase\u002Faspartate aminotransferase\u002Falanine aminotransferase \\>20 × upper limit of normal \\[ULN\\] or bilirubin \\> 10 × ULN). 5. Severe renal impairment (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2).",{"count":297,"type":21},"This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy. Current MRI scans sometimes miss complete tumor response, which can lead to unnecessary surgery. To address this, researchers will use a special MRI technique called hyperpolarized carbon-13 MRI, along with blood and tissue analysis (metabolomics) and advanced image feature analysis (radiomics). These tools can track how cancer cells use energy and how metabolism changes during treatment.\n\nThe study will follow 30 rectal cancer patients at Chang Gung Memorial Hospital over 3 years. Patients will undergo standard MRI, colonoscopy, and advanced metabolic imaging before and after treatment. Results will compare patients whose tumors completely respond to therapy with those who do not. The goal is to see if metabolic changes detected by hyperpolarized MRI and metabolomics can predict treatment outcomes earlier and more accurately. This may help doctors avoid unnecessary surgery and provide more personalized care for rectal cancer patients.",[378],"Neoadjuvant Chemoradiotherapy",[378,380,381,382],"Rectal Cancer","Hyperpolarized 13C-MRI","Pyruvate","2026-07-23",{"date":385,"type":41},"2026-07-28",{"date":387,"type":41},"2026-06-01",{"date":389,"type":21},"2028-07-30",{"name":47,"class":48},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":142,"sex":17,"minAge":398,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":22,"phases":402,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":49},"100648916","dry-cord-care-versus-alcohol-cord-care-in-healthy-newborns-100648916","NCT07728058","Dry Cord Care Versus Alcohol Cord Care in Healthy Newborns","Effects of Routine Umbilical Cord Care and Natural Drying Care on Neonatal Infection Rates, Cord Separation Time, and Cost-Effectiveness: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Healthy neonates with a gestational age of 35 weeks or greater.\n* Birth weight of 2,300 g or greater.\n* Normal umbilical cord appearance at birth, with no evidence of trauma, infection, or congenital abnormalities of the umbilical cord.\n\nExclusion Criteria:\n\n* Neonates born to mothers with intrapartum fever (≥38°C), clinical chorioamnionitis, or rupture of membranes for more than 18 hours\n* Meconium-stained amniotic fluid.\n* Neonates admitted directly to the Newborn Care Center (NBC) or Pediatric Intensive Care Unit (PICU) after birth.\n* Neonates from multiple gestations.","0 Days","28 Days",{"count":401,"type":21},210,[24],"Umbilical cord care is an essential component of newborn care, but the optimal method remains controversial. This randomized controlled trial aims to compare routine alcohol cord care with natural dry cord care in healthy newborns. A total of 210 mother-infant dyads will be randomly assigned to either routine alcohol cord care or natural dry cord care. The primary outcome is the incidence of umbilical cord infection. Secondary outcomes include umbilical cord separation time, bacterial colonization, and healthcare resource utilization for umbilical cord care. The findings of this study will provide evidence to support optimal umbilical cord care practices for healthy newborns.",[405,406],"Umbilical Cord Infection","Newborn",[408,409,410,406,411,405,412,413,414],"Dry Cord Care","Alcohol Cord Care","Umbilical Cord","Randomized Controlled Trial","Cord Separation Time","Bacterial Colonization","Healthcare Resource Utilization","2026-07-22",{"date":417,"type":41},"2026-07-27",{"date":419,"type":41},"2026-07-07",{"date":421,"type":21},"2028-04",{"name":47,"class":48},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":430,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100648806","co-designed-digital-education-and-peer-support-for-young-and-middle-aged-stroke-survivors-100648806","NCT07725666","Co-Designed Digital Education and Peer Support for Young and Middle-Aged Stroke Survivors","A Co-Designed Digital Education and Peer Support Intervention for Reducing Unmet Needs and Enhancing Recovery Among Young and Middle-Aged Stroke Survivors","Inclusion Criteria:\n\n* Aged 31 to 64 years.\n* Diagnosis of stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) and physician diagnosis.\n* Received treatment at the Stroke Center of Linkou Chang Gung Memorial Hospital.\n* Conscious and able to communicate, including individuals with mild aphasia.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* End-stage cancer.\n* Severe aphasia resulting in inability to communicate.\n* Dependent in basic activities of daily living before the index stroke (Barthel Index \\\u003C100), regardless of the underlying cause.","31 Years","64 Years",{"count":433,"type":21},148,[24],"Stroke survivors often experience persistent unmet needs during long-term recovery. Young and middle-aged stroke survivors may face additional challenges in balancing rehabilitation with work and family responsibilities. Although digital health interventions have the potential to improve access to education and self-management support, existing programs are often provider-driven, provide limited peer support, and have short follow-up periods.\n\nThis study aims to evaluate the effectiveness of a patient-centered digital education and peer support intervention co-designed with young and middle-aged stroke survivors. Participants will be randomly assigned to either the intervention group or the usual care group. The intervention will be delivered through LINE communities and Google collaborative platforms over a 12-month period. The primary outcome is unmet needs. Secondary outcomes include stroke self-efficacy, depressive symptoms, quality of life, activities of daily living, instrumental activities of daily living, and return-to-work status.",[437,438],"Stroke","Stroke (6 Months or More After Onset)",[437,440,441],"Digital Health","Peer Support","2026-07-21",{"date":444,"type":41},"2026-07-24",{"date":446,"type":21},"2026-08",{"date":448,"type":21},"2029-07",{"name":47,"class":48},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":142,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":459,"conditions":460,"keywords":463,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":49},"100648802","hyperpolarized-mri-for-gist-on-imatinib-100648802","NCT07724626","Hyperpolarized MRI for GIST on Imatinib","Integrated Precision Imaging for GIST Patients on Imatinib Therapy: Combining Hyperpolarized 13C-MRI, Metabolomics, and Radiomics","DNP_GIST","Inclusion Criteria:\n\n1. Patients with biopsy proved GIST.\n2. Patents will undergo imatinib.\n3. Patients have measurable disease on imaging study.\n4. Patients more than 18-year-old.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding women.\n2. Contraindication to MRI study (e.g., claustrophobia or non-removable devices or implants that are incompatible with MRI).\n3. Intercurrent illness that will affect the compliance of the patient during the MRI study (e.g., active infection, symptomatic congestive heart failure, uncontrollable angina, arrhythmia, psychiatric disorders, dyspnea, or diarrhea).\n4. Severe hepatic dysfunction (alkaline phosphatase\u002Faspartate aminotransferase\u002Falanine aminotransferase \\>20 × upper limit of normal \\[ULN\\] or bilirubin \\> 10 × ULN).\n5. Severe renal impairment (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2).",{"count":297,"type":21},"Conventional imaging methods, such as CT and MRI, are limited in evaluating GIST response to imatinib, as they mainly reflect tumor size and fail to capture early metabolic or molecular changes. This study investigates GISTs from a metabolic perspective by integrating hyperpolarized (HP) 13C-MRI, metabolomics, and radiomics. HP 13C-MRI enables real-time monitoring of metabolic flux in vivo, while NMR-based metabolomics provides systemic insights. In this single-center, prospective observational cohort study, 30 GIST patients receiving imatinib will undergo pre-treatment CT, HP 13C-MRI, metabolomics, and biopsy. Early response will be assessed at one month, with routine evaluation at four months. Patients will be categorized as responders or non-responders, and multi-omics data will be analyzed using machine learning. The study hypothesizes that metabolic changes detected by HP 13C-MRI can predict treatment response, offering reproducible, quantifiable metrics to improve evaluation and patient care.",[461,462],"Imatinib Therapy Response","Gastrointestinal Stromal Tumor (GIST)",[462,464,381,465,466],"Imatinib Therapy","Dynamic Nuclear Polarization (DNP)","Radiomics",{"date":444,"type":41},{"date":469,"type":21},"2027-01-01",{"date":471,"type":21},"2028-10-31",{"name":47,"class":48},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":142,"sex":17,"minAge":165,"maxAge":348,"enrollmentInfo":480,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":489,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":500,"locationsCount":49},"100646521","investigating-the-effectiveness-of-personalized-optimal-gamma-auditory-frequency-stimulation-intervention-on-cognitive-function-enhancement-100646521","NCT07690865","Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement","Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement: An Intervention Study","Inclusion Criteria:\n\n1. Age between 18 to 40 years old.\n2. The Cognitive Abilities Screening Instrument (CASI) score is within normal ranges adjusted for age and education.\n3. Participants have no history of severe neurological or psychiatric disorders (such as stroke, epilepsy, depression, migraine, etc.) that could affect cognitive function.\n4. Participants have not used drugs that may affect cognitive function (e.g., benzodiazepines, anticholinergic medications, etc.).\n5. Participants with normal or corrected vision (e.g., glasses or contact lenses) to normal levels.\n6. Auditory stimuli induce significant neural entrainment.\n7. Self-reported normal hearing\n\nExclusion Criteria:\n\n1. Participants enrolled in any cognitive enhancement study within the past two months.\n2. Participants with a history of disease that could affect cognitive function (e.g., cancer, autoimmune diseases, etc.).\n3. Individuals with tinnitus or hyperacusis",{"count":481,"type":21},20,[24],"This study aims to evaluate whether personalized gamma-frequency auditory stimulation enhances cognitive function and brain synchronization. While 40 Hz auditory stimulation has been widely studied, recent evidence suggests optimal frequencies vary by individual. Using a cross-over design with 20 healthy adults, the research compares \"optimal\" versus \"non-optimal\" frequencies over one-month intervention periods. Effectiveness is measured through EEG recordings and executive function tasks. The goal is to determine if personalized sensory intervention provides a more effective, non-invasive strategy for enhancing cognitive performance.",[485,486,487,488],"Gamma Oscillations","Healthy Adults","Alzheimer's Disease (AD)","Gamma Entrainment Using Sensory Stimuli (GENUS)",[490,491,492,493,494],"Gamma stimulation","Alzheimer's disease","EEG","cognitive function","intervention","2026-07-15",{"date":497,"type":41},"2026-07-16",{"date":446,"type":21},{"date":340,"type":21},{"name":47,"class":48},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":508,"maxAge":59,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":528,"leadSponsor":530,"locationsCount":531},"100647242","phase-1-safety-and-dose-response-of-bletilla-formosana-in-prediabetic-subjects-100647242","NCT07704944","Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects","A Phase I\u002FII Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects","Inclusion Criteria:\n\n1. Adults aged 30-70 years.\n2. Prediabetes defined by any of the following:\n3. Fasting Plasma Glucose (FPG) of 100-125 mg\u002FdL, or\n4. Glycated hemoglobin (HbA1c) of 5.7%-6.4%.\n5. Willingness to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Established type 1 or type 2 diabetes mellitus, or recent use of oral antidiabetic agents or insulin (within 3 months).\n2. Abnormal liver function, defined as Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) exceeding 2-fold the upper reference limit (≥2 × ULN) at screening.\n3. Abnormal renal function, defined as serum creatinine (Cr) \\>1.5 mg\u002FdL or Estimated Glomerular Filtration Rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m².\n4. Gastrointestinal disorders that may affect drug absorption, such as gastrostomy, enterostomy, severe chronic diarrhea, or malabsorption syndrome.\n5. Severe comorbidities within the past 6 months, including major stroke, myocardial infarction, major trauma, or major surgery.\n6. Recent use of medications (within 1 month) that may significantly alter blood glucose or lipids, such as systemic corticosteroids or non-stable doses of lipid-lowering agents.\n7. Malignant tumor under active treatment, or immunodeficiency\u002Fautoimmune disorders requiring immunosuppressive therapy.\n8. Psychiatric disorders or cognitive impairment that may affect protocol compliance.\n9. Active use of other investigational drugs within 3 months prior to screening.\n10. Pregnancy or lactation.","30 Years",{"count":510,"type":21},94,[512,63],"PHASE1","This study evaluates the safety and preliminary efficacy of Bletilla formosana (BF), a traditional herbal medicine, in adults with prediabetes. Prediabetes is a high-risk condition where blood sugar levels are elevated, often leading to type 2 diabetes. While lifestyle changes are the standard treatment, researchers are exploring herbal supplements as a complementary way to support metabolic health. Preclinical research has shown that BF possesses anti-inflammatory properties and may help regulate blood glucose. Participants in this study will be randomly assigned to receive either a high dose of BF, a low dose of BF, or a placebo (an inactive substance) for 12 weeks. The total study duration is approximately 24 weeks, involving four clinic visits for blood tests and safety monitoring to see how BF affects blood sugar markers and inflammation.",[515],"Prediabetes",[515,517,518,519,520,521,522,523,411,524],"Bletilla formosana","Traditional Chinese Medicine","Herbal Medicine","Glycemic Control","Anti-inflammatory","Dose-Response Relationship","Phase I\u002FII Trial","Safety and Tolerability","2026-07-14",{"date":495,"type":41},{"date":258,"type":21},{"date":529,"type":21},"2027-08-01",{"name":47,"class":48},3,{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":49},"100611269","evaluation-of-nystagmus-examination-using-wearable-ar-glasses-in-vertigo-patients-100611269","NCT07238387","Evaluation of Nystagmus Examination Using Wearable AR Glasses in Vertigo Patients","Evaluation of Nystagmus Examinations Conducted Using Wearable Augmented Reality Glasses in Vertigo Patients: A Randomized Equivalence Study","Inclusion Criteria:\n\n* Adults ≥18 years with vertigo\u002Fdizziness suggestive of a central or peripheral vestibular disorder.\n* Able to complete both AR-based and conventional oculomotor testing during the same visit (with \\~30-minute washout).\n* Provide written informed consent.\n* Adequate vision for eye-tracking and calibration (e.g., corrected visual acuity ≥20\u002F40 in each eye).\n* Willing and able to return for the follow-up visit.\n\nExclusion Criteria:\n\n* Use of vestibular-suppressant medications within 24 hours prior to testing (e.g., benzodiazepines, antihistamines, anticholinergics).\n* Ocular conditions that would interfere with reliable eye tracking (e.g., corrected visual acuity \\\u003C20\u002F40, dense cataract, severe ptosis\u002Fstrabismus, active ocular infection\u002Finflammation).\n* History of photosensitive epilepsy or seizure disorder triggered by visual stimuli.\n* Severe motion sickness\u002Fcybersickness or inability to tolerate the AR headset.\n* Significant cognitive impairment or psychiatric condition precluding informed consent or protocol compliance.\n* Pregnant or breastfeeding (per investigator judgment and IRB policy).\n* Any other condition that, in the investigator's opinion, would make participation unsafe or confound study results.",{"count":540,"type":21},200,[24],"Background and Purpose:\n\nVertigo is common in emergency and outpatient settings, yet standard oculomotor testing usually requires dedicated equipment and exam rooms. This study evaluates whether nystagmus examinations performed with wearable augmented-reality (AR) glasses are equivalent to conventional examination-room testing for classifying central vs. peripheral vertigo. The investigators also assess diagnostic accuracy, patient tolerability, and the reliability of AR-based interpretation (test-retest and inter-rater).\n\nStudy Design:\n\nProspective, single-center, within-subject randomized equivalence study at Kaohsiung Chang Gung Memorial Hospital. Each participant completes both AR-based and conventional oculomotor testing in a randomized order during the same visit, separated by a 30-minute washout. The study uses an evaluator-blind approach: de-identified trajectories are reviewed offline by independent experts who are masked to test modality. A follow-up visit (\\~1 week) captures adverse events and patient experience.\n\nParticipants:\n\nAdults (≥18 years) presenting with vertigo who can tolerate the AR headset and provide consent. Key exclusions include conditions that prevent reliable eye-tracking (e.g., corrected visual acuity \\\u003C20\u002F40), recent use of vestibular suppressants (within 24 hours), and other factors limiting cooperation or safety.\n\nInterventions and Procedures:\n\nThe AR system records eye movements and presents standardized visual stimuli. Conventional testing follows current clinical standards (e.g., Frenzel\u002Foculomotor exam). All recordings are stored securely for blinded review.\n\nOutcomes:\n\nPrimary endpoint: Equivalence of diagnostic agreement (central vs. peripheral) between AR-based and conventional methods, quantified by Cohen's kappa (κ) with a predefined equivalence margin.\n\nSecondary endpoints: (1) Diagnostic accuracy of the AR method in a clinically-indicated imaging subgroup (MRI preferred; CT as needed) using a sequential evaluation strategy; (2) Patient discomfort\u002Ftolerability using VAS and CSQ-VR, compared between modalities; (3) Test-retest reliability of AR-based classifications; (4) Inter-rater reliability between independent evaluators, with a third reader adjudicating discordant cases; (5) prespecified subgroup analyses by age, medical history, and vestibular function.\n\nSample Size and Duration:\n\nApproximately 200 participants will be enrolled (target \\~180 evaluable after \\~10% attrition). Total study duration is \\~2 years, including enrollment, follow-up, and analysis.\n\nRisks and Benefits:\n\nBoth tests are non-invasive. Potential transient discomfort (e.g., eye strain or cybersickness) will be monitored. There may be no direct benefit to participants; however, results could support broader, more accessible, and standardized vertigo assessment.\n\nData Security and Privacy:\n\nAll data are de-identified, stored on secure platforms with role-based access and audit trails. Safety events are monitored and graded, and protocol deviations are handled per Good Clinical Practice.",[544,545,546],"Vertigo","Vestibular Disorder","Nystagmus","2026-07-08",{"date":549,"type":41},"2026-07-09",{"date":551,"type":41},"2026-01-01",{"date":553,"type":21},"2029-12-31",{"name":47,"class":48},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":562,"maxAge":508,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":577,"leadSponsor":579,"locationsCount":156},"100646639","phase-1-dinutuximab-beta-and-chemotherapy-in-newly-diagnosed-high-risk-neuroblastoma-100646639","NCT07688252","Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma","Pilot Study of Combining of Dinutuximab-β With Induction Chemotherapy in Newly Diagnosed High Risk Neuroblastoma","Inclusion Criteria:\n\n1. Must be 1 to 30 years of age at the time of initial diagnosis.\n2. Must have histological verification of neuroblastoma or ganglioneuroblastoma, OR demonstration of neuroblastoma cells in the bone marrow with elevated urinary VMA at the time of initial diagnosis.\n3. Must have newly diagnosed high-risk neuroblastoma according to the revised COG NBL risk classifier (version 2), defined as meeting at least ONE of the following:\n\n   1. INRG Stage M: MYCN amplification (\\> 4-fold increase), OR age 12 to \\\u003C 18 months without MYCN amplification but with unfavorable histology\u002FDI = 1\u002FSCA, OR age \\> 18 months regardless of biologic features.\n   2. INRG Stage MS: MYCN amplification, OR age 12 to \\\u003C 18 months without MYCN amplification but with unfavorable histology\u002FDI = 1\u002FSCA.\n   3. INRG Stage L2: MYCN amplification, OR age 18 months to \\\u003C 5 years without MYCN amplification but with unfavorable histology, OR age ≥ 5 years without MYCN amplification but with unfavorable histology (undifferentiated or poorly differentiated tumor).\n   4. INRG Stage L1: Tumor with incomplete resection and MYCN amplification.\n   5. Patients \\> 18 months of age initially diagnosed with INRG Stage L1, L2, or MS who are subsequently upgraded to high-risk disease.\n4. Must have had no prior systemic therapy, or have only completed the first cycle of induction chemotherapy under the TPOG N2020-HR protocol.\n5. Must have measurable disease, defined as at least ONE of the following (Note: Patients with elevated VMA only are NOT eligible):\n\n   1. Measurable tumor on MRI or CT scan within 3 weeks prior to study entry (≥ 10 mm in at least one dimension) that is MIBG avid or demonstrates increased FDG\u002FFDOPA uptake on PET scan.\n   2. MIBG or FDG\u002FFDOPA PET scan within 2 weeks prior to study entry with positive uptake at a minimum of one site.\n6. ECOG Performance Status of 0, 1, or 2.\n7. Adequate organ function, including:\n\n   1. Renal: Creatinine clearance or estimated GFR ≥ 60 mL\u002Fmin\u002F1.73 m², or serum creatinine ≤ upper limit of normal (ULN) based on age\u002Fgender.\n   2. Liver: Total bilirubin ≤ 1.5 x ULN for age AND SGPT (ALT) ≤ 5.0 x ULN (if liver tumor is present) or ≤ 3.0 x ULN (if no liver tumor).\n   3. CNS: No clinical or radiological evidence of active CNS disease (well-controlled seizures allowed), and CNS toxicity ≤ Grade 2.\n   4. Cardiac: Shortening fraction ≥ 27% or Ejection fraction ≥ 50% by ECHO or gated radionuclide study.\n   5. Pulmonary: No dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry \\> 94%.\n8. Must be enrolled on the TPOG N2020-GD2 protocol with completed informed consent forms, and be willing to proceed to standard therapy of high-risk neuroblastoma with a 10-year follow-up.\n\nExclusion Criteria:\n\n1. Participation in other interventional clinical trials within 1 month.\n2. Inability to obey the trial instructions.\n3. Patients with bone marrow failure syndromes.\n4. Current requirement for immunosuppressive medications (e.g., tacrolimus, cyclosporine, systemic corticosteroids for reasons other than prevention\u002Ftreatment of acute allergic reactions or adrenal replacement therapy).\n5. Females who are pregnant or breastfeeding (A pregnancy test is required for female patients of childbearing potential).\n\n   1. Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.\n   2. Lactating females who plan to breastfeed their infants.\n   3. The subject or their partner is planning to conceive\n   4. Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method during study therapy and for two months after the last dose of (ch14.18\u002FCHO) (dinutuximab-β) are not eligible.","1 Year",{"count":297,"type":21},[512],"This clinical trial investigates the safety, side effects, and effectiveness of combining an immunotherapy drug called dinutuximab-beta with standard induction chemotherapy for patients newly diagnosed with high-risk neuroblastoma. Dinutuximab-beta is an antibody designed to target specific molecules on the surface of neuroblastoma cells.\n\nIn this pilot study, enrolled patients will receive dinutuximab-beta as a continuous intravenous infusion alongside a standard 6-cycle induction chemotherapy regimen. The primary goals of this study are to monitor how well patients tolerate the new combination treatment closely and to determine how effectively tumors shrink before patients proceed to the next phase of their standard consolidation therapy.",[567],"High Risk Neuroblastoma",[569,570,571,572,573],"Neuroblastoma","High-risk","chemoimmumotherapy","newly-diagnosed","dinutuximab-beta","2026-06-30",{"date":419,"type":41},{"date":258,"type":21},{"date":578,"type":21},"2032-12-31",{"name":47,"class":48},{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":142,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":588,"targetDuration":590,"studyType":119,"phases":4,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":49},"100260801","ocean-registry-obesity-and-clock-for-elegant-aging-registry-100260801","NCT02674230","OCEAN Registry: Obesity and Clock for Elegant Aging Registry","OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫","OCEAN","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* Body mass index ≥ 24 kg\u002Fm2\n* For normal subjects, Body mass index \\\u003C 24 kg\u002Fm2\n\nExclusion Criteria:\n\n* No inform consent\n* Use of steroid medications\n* Severe systemic diseases or organ failure with estimated life expectancy of 6 months or less",{"count":589,"type":21},2000,"10 Years","This study aims to study the relationships between obesity, circadian rhythm, and aging. The investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. The cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. Clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.",[593,594,355,595],"Obesity","Circadian Dysregulation","Cardiovascular Disease","2026-06-18",{"date":598,"type":41},"2026-06-23",{"date":600,"type":4},"2011-07",{"date":602,"type":21},"2035-06",{"name":47,"class":48},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":22,"phases":613,"briefSummary":614,"conditions":615,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":622,"leadSponsor":624,"locationsCount":4},"100641582","the-anorectal-function-and-qol-of-patients-receiving-transrectal-nose-via-rigid-tamis-platform-in-minimal-invasive-colon-surgery-100641582","NCT07653607","The Anorectal Function and QoL of Patients Receiving Transrectal NOSE Via Rigid TAMIS Platform in Minimal Invasive Colon Surgery","A Prospective, Multi-Center, Single-Arm, Open-Label Study to Analyze Anorectal Function and Quality of Life in Patients Undergoing Minimally Invasive Colectomy With Transrectal Natural Orifice Specimen Extraction (NOSE) Using a Rigid Transanal Minimally Invasive Surgery (TAMIS) Platform","Inclusion Criteria:\n\n1. Male or female, aged above 18 years, inclusive.\n2. Patients scheduled for an elective laparoscopic or robotic-assisted colectomy above sigmoid colon.\n3. Deemed a suitable candidate for the Transrectal NOSE procedure by the treating surgical team, based on tumor size (generally, largest diameter \\\u003C 4 cm), tumor T stage(1-3), location, and patient anatomy.\n4. American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Able to understand the purpose, procedures, potential risks, and benefits of the study and willing to provide written informed consent, as approved by the Institutional Review Board (IRB).\n6. Willing and able to comply with all scheduled follow-up visits and assessment procedures outlined in the protocol.\n\nExclusion Criteria:\n\n1. Pre-existing moderate-to-severe fecal incontinence, defined as a Wexner incontinence score \\> 8.\n2. History of any prior anal surgery (e.g., sphincteroplasty, artificial sphincter implantation, fistulotomy), major pelvic surgery (e.g., hysterectomy, radical prostatectomy), or pelvic radiation therapy.\n3. Confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis).\n4. The planned surgical procedure requires a protective stoma.\n5. Uncorrectable coagulopathy identified on preoperative assessment.\n6. Known neurological condition affecting bowel control (e.g., spinal cord injury, multiple sclerosis, significant post-stroke deficits).\n7. Cognitive impairment, severe psychiatric illness, or other condition that would interfere with reliable completion of questionnaires or compliance with the protocol.\n8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period.\n9. Concurrent participation in another interventional clinical trial that could potentially interfere with the study outcomes.\n10. Any other condition which, in the professional opinion of the investigator, makes the subject unsuitable for participation in this study.",{"count":612,"type":21},57,[24],"The primary objective of this study is to prospectively determine and precisely estimate the incidence of Internal Anal Sphincter (IAS) Injury at 12 months following colectomy with Transrectal NOSE.",[616,617],"Minimal Invasive Surgery","Colon Surgery","2026-06-15",{"date":620,"type":41},"2026-06-17",{"date":387,"type":21},{"date":623,"type":21},"2029-07-31",{"name":47,"class":48},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":142,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":634,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":49},"100642700","fnirs-for-monitoring-cortical-activity-in-stroke-recovery-100642700","NCT07623512","fNIRS for Monitoring Cortical Activity in Stroke Recovery","Functional Near-infrared Spectroscopy (fNIRS) is an Ideal Tool to Monitor Cortical Brain Activity and Understand the Mechanism Underlying Recovery Following Stroke","Stroke participants\n\nInclusion Criteria:\n\n* unilateral stroke onset ≥ 3 months\n* Fugl-Meyer Assessment for Upper Extremity (FMA-UE) score between 18 to 56 - modified Ashworth scale ≤ 3 in proximal joints and modified Ashworth scale ≤ 2 in distal joints\n* able to follow 2-step instructions\n* without excessive spasticity in any of the UE joints.\n\nExclusion Criteria:\n\n* orthopedic conditions affecting the arm\u002Fhand or other neurological conditions\n* severe pain that prevents movement in the affected arm and hand\n* implanted cardiac pacemakers and cardioverter-defibrillators\n* osteoporosis, fracture, or severe ataxia\n* unstable medical status\n* participating in other rehabilitation or drug studies simultaneously\n* receiving Botulinum toxin injections within 3 months\n\nHealthy participants\n\n* have no neurological conditions\n* have no musculoskeletal disorders affecting the UE",{"count":633,"type":21},108,[24],"This clinical trial aims to investigate the mechanisms of brain reorganization underlying motor recovery following end-effector (EE) and exoskeleton (Exo) robot-assisted hand training in individuals with stroke. Using functional near-infrared spectroscopy (fNIRS), the study will (1) investigate brain activation patterns during EE and Exo robot-assisted hand movements in healthy adults and individuals with stroke and (2) examine longitudinal changes in brain activation and motor recovery over a 6-week intervention.\n\nFor Part 1, a cross-sectional observational study will be conducted to examine brain activation using fNIRS while participants perform EE and Exo robot-assisted movements. Healthy adults and individuals with stroke will each perform one session of each type of robot-assisted movement.\n\nFor Part 2, an evaluator-blinded randomized controlled design will be used. Participants will be stratified based on the level of motor impairment and the side of the brain lesion and then randomly assigned to either the EE or Exo robot-assisted training group. Both groups will receive training 3 times per week, with each session lasting 60 minutes, for a total of 6 weeks. Each session will include 40 minutes of robot-assisted therapy and 20 minutes of functional training.\n\nOutcome assessments will be conducted at four time points: prior to the intervention (baseline), mid-intervention (during weeks 3-4 of the intervention), immediately after the intervention, and at the 3-month post-trial follow-up. These assessments will be used to evaluate motor recovery and longitudinal changes in brain function.",[437],"2026-06-14",{"date":639,"type":41},"2026-06-16",{"date":641,"type":41},"2025-11-28",{"date":365,"type":21},{"name":47,"class":48},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":142,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":666,"completionDateStruct":667,"leadSponsor":669,"locationsCount":49},"100642761","the-effectiveness-of-a-digital-career-focused-mobile-application-on-nursing-students-career-planning-and-career-trajectories--100642761","NCT07628673","The Effectiveness of a Digital Career-Focused Mobile Application on Nursing Students' Career Planning and Career Trajectories .","NurseBridge","Inclusion Criteria:\n\n* Currently in their final year of nursing studies (including five-year vocational colleges, four-year technical colleges, and universities).\n* Possess a mobile phone with internet access.\n* Be of sound mind and able to understand and answer researchers' questions.\n* Be able to understand spoken or written Chinese.\n* Be willing to participate in this study and sign a participant consent form.\n\nExclusion Criteria:\n\n* Nursing two-year technical college students.\n* Those with full-time or part-time clinical nursing work experience.\n* Those unwilling to participate in this study.",{"count":433,"type":21},[24],"Methods: This three-year experimental study is divided into two phases. In the first phase, a mixed-methods approach will be used. During this phase, a mobile application based on the Career Planning Model will be developed, followed by a pilot study to perform user testing and evaluate usability. The second phase will employ a prospective, double-blind randomized controlled trial (RCT) design, utilizing the nursing career planning application developed in the first phase for a six-month intervention study. A total of 108 senior-year nursing students (54 in the intervention group and 54 in the control group) will be invited to participate inthe study.",[655],"This Study Will Develop Nurse Bridge and Test Its Six-month Effects on Nursing Students' Career Outcomes Using a Two-phase Randomized Controlled Trial",[657,658,659,660,661,662,663],"career planning behaviors","career resilience","professional identity","nursing career persistence intentions","career self-efficacy","persistence intentions","nursing students' study","2026-06-12",{"date":618,"type":41},{"date":258,"type":21},{"date":668,"type":21},"2029-10-30",{"name":47,"class":48},""]